Sign in
Taking peopleNo phase

Early Diagnosis of Invasive Lung Aspergillosis

Key facts

Who runs it
University Hospital Ostrava
Where
Czechia7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
150 people, planned
Started
31 May 2023
Expected to end
31 Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • Next generation improvement of early invasive aspergillosis
Record updated
7 September 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • respiratory rate ≥ 30 breaths/min
  • PaO2/FiO2 ratio ≤ 250
  • multilobar infiltrates
  • confusion/disorientation
  • uremia (blood urea nitrogen level ≥ 20mg/dL)
  • leucocytosis (white blood cell count > 12000/mL) or
  • leukopenia (white blood cell count < 4 x 109/L)
  • thrombocytopenia (platelet count < 100 x 109/L)
  • hyperthermia (core temperature > 38 °C)
  • hypothermia (core temperature < 36 °C)
  • hypotension requiring aggressive fluid resuscitation
  • invasive mechanical ventilation and septic shock requiring vasopressors
  • Bronchoalveolar Lavage Fluid (BALF) and/or Endotracheal Aspirate (ETA)

Who cannot take part

  • patients, in whom PTX3, Aspergillus qPCR, and HPLC-FTICR were not performed or were performed after the start of antifungal treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in severe respiratory infections (H1N1, COVID-19, bacterial infections). This is most evident in critically ill patients whose life is threatened by invasive pulmonary aspergillosis (IPA), with over 90 % of cases being caused by Aspergillus fumigatus. In recent decades, various biomarkers with well-known limits of use (Aspergillus DNA, galactomannan, 1,3-ß-D-glucan) have been used for early diagnosis of IPA. However, the clinical need to clearly distinguish the onset of IPA from colonization is much more significant. The current biomarkers only provide "probable IPA" interpretation, and the diagnosis is rarely confirmed. Based on our preliminary studies, the use of new low molecular weight substances (secondary metabolites) combined with acute-phase proteins (pentraxin 3) allows very reliable immediate confirmation of IPA. In tissue samples, bronchoalveolar lavage fluid, endotracheal aspirate, breath condensate, serum, and urine of critically ill patients, the investigators will be able to recognize and confirm IPA in time using highly sensitive mass spectrometry detecting specific microbial siderophores in correlation with a significantly increased concentration of acute-phase host protein (pentraxin 3) within hours of the beginning of the invasion of lung tissue. Through a prospective multicentre study, the investigators will evaluate the benefit of new biomarkers in non-invasive IPA confirmation, improve the IPA diagnostic algorithm and transfer the detection method to MALDI-TOF spectrometers widely used in Clinical laboratories in the Czech Republic. In MALDI-TOF mass spectrometry, the ion source is matrix-assisted laser desorption/ionization (MALDI), and the mass analyser is a time-of-flight (TOF) analyser.

Read full original descriptionShow less

The study results will contribute to a high clarity of IPA cases, the accurate introduction of antifungal therapy, and a better prognosis of survival of critically ill patients.

The 2 groups in the trial

  • Suspicion of IPA at enrolment

    Study subjects with suspicion of IPA at enrolment will be included in this study group.

    Treatment: Next generation improvement of early invasive aspergillosis

  • Probable or proven IPA at enrolment

    Study subjects with probable or proven IPA at enrolment will be included in this study group.

    Treatment: Next generation improvement of early invasive aspergillosis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 September 2023